PRESS RELEASE
23 February 2026

PCC clears GCMC-Leapfrog healthcare joint venture

On January 8, 2026, the Philippine Competition Commission (PCC) cleared the proposed joint venture among GCMC Holdings, Inc. (GCMC), Navegar II (Singapore) Pte. Ltd. (Navegar II Singapore), and Leapfrog Emerging Consumer Fund IV, LP (Leapfrog), following a Phase 1 review by the PCC’s Mergers and Acquisitions Office (MAO).

GCMC is a holding company operating hospitals and medical services across the Philippines, including diagnostic services and the distribution of pharmaceuticals and medical equipment. Navegar II Singapore is a private equity firm based in Singapore with diverse investments in various Philippine businesses and industries. Leapfrog, also registered in Singapore, is likewise a private equity firm, which focuses on high-impact healthcare and financial services investments in global growth markets.

The MAO’s review found no horizontal overlaps or vertical relationships between the parties. GCMC and Navegar II operate in distinct, non-overlapping market segments, while Leucadendron, as an investment holding company, currently has no operations in the Philippines. The transaction does not affect market positions or competitive dynamics in any relevant market.

Review of mergers and acquisitions, including joint ventures, underscores the PCC’s role in evaluating cross-border investments and strategic partnerships that impact critical sectors in the country ensuring competitive market conditions, ensuring competitive market conditions.

###

REFERENCE:  
publicaffairs@phcc.gov.ph  
Public Affairs and Research Division
Communications and Knowledge Management Office
Philippine Competition Commission